Introduction {#Sec1}
============

Patients requiring hemodialysis are at an increased risk of acquiring hepatitis C virus (HCV)^[@CR1]^. Approximately 5% of patients on hemodialysis are diagnosed with HCV, compared to 1% in the United States population^[@CR2],[@CR3]^ and, among hemodialysis patients, HCV infection is associated with poor outcomes with substantially higher rates of hepatic-related mortality and hospitalizations, and lower health-related quality of life scores, compared to HCV negative hemodialysis patients^[@CR4]^.

National guidelines for the treatment of HCV infection among hemodialysis patients recommend several direct-acting antivirals (DAA)^[@CR5],[@CR6]^. Sofosbuvir (SOF)-based regimens are not recommended for patients requiring hemodialysis since renal clearance of SOF is the major elimination pathway, although since the recent U.S. Federal Drug Administration change in label, removing restrictions on its use in renal impairment, this will undoubtedly change^[@CR7]^. Nevertheless, clinical studies provide evidence that use of SOF, among HCV positive patients with renal impairment, is effective and safe^[@CR8],[@CR9]^. Data focusing only on patients requiring maintenance hemodialysis are limited. Thus, we performed a systematic review and meta-analysis to quantify the efficacy and safety of SOF-based regimens among the subset of patients with severe renal impairment that required maintenance hemodialysis.

Results {#Sec2}
=======

Our systematic search yielded 777 studies of which 60 were eligible for full text review. A total of 20 studies were in accordance with our eligibility criteria and were included in the meta-analysis (Table [1](#Tab1){ref-type="table"}). The selection process is detailed in Fig. [1](#Fig1){ref-type="fig"}.Table 1Summary of study and patient characteristics.StudyStudy periodType of studyCountryPopulation (N)Age (mean)Male (%)Genotype (%)Combination drugsSofosbuvir doseSVR12 N (%)Agarwal et al*.*^[@CR14]^2015--2016ProspectiveIndia6233.866.1GT-1: 65, GT-2: 2, GT-3: 29, GT-4: 3, GT-6: 2RBV, DCV400 mg AD, 400 mg daily59 (95%)Akhil et al*.*^[@CR10]^2015--2016RetrospectiveIndia2249.7668.2GT-1: 64, GT-3: 27, GT-4: 9RBV, DCV400 mg daily16 (73%)Bhamidimarri et al*.*^[@CR15]^2014--2015ProspectiveUSA1059.791.7GT-1a: 67, GT-1b: 33SMV200 mg daily, 400 mg AD10 (83%)Choudhary et al*.*^[@CR16]^2015--2016ProspectiveIndia256.5100GT-1: 50, GT-3: 50,DCV400 mg AD2 (100%)Desnoyer et al*.*^[@CR17]^2014--2015ProspectiveFrance1254.483.3GT-1: 92, GT-2: 8SMV, DCV, LDV, RBV400 mg daily, 400 mg 3 times/week10 (83%)Gupta et al*.*^[@CR18]^2015--2016ProspectiveIndia748.471.4GT-1: 57, GT-3: 43DCV, RBV200 mg daily6 (86%)He et al*.*^[@CR19]^2016ProspectiveChina3352.872.7GT-1a: 21, GT-2a: 73, GT-1b + 2a:6DCV200 mg daily33 (100%)Mehta et al*.*^[@CR20]^2016ProspectiveIndia3849.568.4GT-1a: 42, GT-1b: 58LDV, DCV400 mg daily, 400 mg AD33 (87%)Sperl et al*.*^[@CR11]^2015--2016RetrospectiveCzech Republic639100GT-3:100DCV200 mg daily6 (100%)Surendra et al*.*^[@CR22]^2015ProspectiveIndia214461.9GT-1a: 57, GT-1b: 33LDV400 mg AD19 (90%)Singh et al*.*^[@CR21]^2014--2015ProspectiveUSA856.825GT-1a: 38, GT-1b: 38, GT-3: 13, GT-4:13SMV, LDV400 mg daily7 (88%)Borgia et al*.*^[@CR23]^2017--2018ProspectiveCanada, UK, Spain, Israel, New Zealand, Australia596035GT-1a: 25, GT-1b: 19, GT-2: 12, GT-3: 32, GT-4: 7, GT-6: 3VPV400 mg daily56(95%)Seo et al*.*^[@CR13]^2017--2018RetrospectiveKorea959.966.7GT-2:100RBV400 mg daily9 (100%)Lin et al*.*^[@CR27]^2017ProspectiveChina75371.4GT-1b: 57, GT-2a: 29, GT-6: 14DCV, LDV400 mg daily6 (86%)Debnath et al*.*^[@CR25]^2017--2018ProspectiveIndia1839.477.8%GT-1: 66.7, GT-2: 5.5, GT-3: 22.3, GT-5: 5.5DCV, LDV400 mg daily18 (100%)Singh et al*.*^[@CR29]^2015--2017ProspectiveIndia3939.683%GT-1: 68, GT-3: 28, GT-4: 4.3DCV, LDV400 mg daily37 (95%)Mandhwani et al*.*^[@CR28]^2016--2018ProspectivePakistan7331.972.9%GT-1: 50.3, GT-2: 0.7, GT-3: 42.9, GT-4: 1.48DCV, RBV400 mg daily70 (96%)Hussein et al*.*^[@CR26]^2017ProspectiveIraq1954.863%GT-1a:100DCV, LDV200 mg daily, 400 mg daily19 (100%)Gaur et al*.*^[@CR12]^2017--2018RetrospectiveIndia3139.877.5%GT-1: 67.7, GT-3: 32.2VPV400 mg daily30 (97%)Cheema et al*.*^[@CR24]^2017--2018ProspectivePakistan3647.22 Group 1 53.89 Group 261.1%GT-1: 33.3, GT-2: 2.8, GT-3: 63.9DCV400 mg daily (Group 1), 400 mg 3 times/week (Group 2)29 (80%)*NR* Not reported, *GT* genotype, *SVR12* sustained virologic response 12 weeks after treatment, *AD* alternate day, *RBV* ribavirin, *SMV* simeprevir, *LDV* ledipasvir, *DCV* daclatasvir, *VPV* velpatasvir.Figure 1Flow diagram for selection of studies included in the systematic review and meta-analysis. *SVR* sustained virologic response, *AE* adverse events.

The included studies were published from 2015 to 2020 and contained extractable data on 514 patients enrolled from 2014 to 2016. Four studies were retrospective^[@CR10]--[@CR13]^ and 16 were prospective^[@CR14]--[@CR29]^. Nine of the studies were conducted in India^[@CR10],[@CR12],[@CR14],[@CR16],[@CR18],[@CR20],[@CR22],[@CR25],[@CR29]^, 2 in the USA^[@CR15],[@CR21]^, 2 in Pakistan^[@CR24],[@CR28]^, 2 in China^[@CR19],[@CR27]^, 1 in France^[@CR17]^, the Czech Republic^[@CR11]^, Korea^[@CR13]^, Iraq^[@CR26]^, and 1 enrolled patients from multiple countries^[@CR23]^. All studies received more than five stars in the Newcastle--Ottawa Scale and no study was excluded due to quality concerns.

The overall pooled estimate of the efficacy of SOF-based therapy among HCV positive patients on maintenance hemodialysis was 95% (95% CI 91--98%), ranging from 73 to 100% (Fig. [2](#Fig2){ref-type="fig"}). There was moderate heterogeneity among studies (I^2^ = 40.3%, p \< 0.05). A meta-regression analysis did not demonstrate any evidence that the differences in gender, age, HCV genotypes, or type of SOF-based regimens among studies were correlated with the between study heterogeneity (p = 0.97). Egger's test for publication bias yielded insignificant results (bias = − 0.76, p = 0.46), suggesting absence of small-study effects.Figure 2Forest plot of included studies. Individual and combined estimates of the efficacy of sofosbuvir-based therapy with 95% confidence intervals. *ES* effect size (efficacy).

A total of 19 studies reported extractable data on the SOF dose^[@CR10]--[@CR14],[@CR16]--[@CR29]^ and the other DAA included in the treatment regimen. In nine studies^[@CR10]--[@CR13],[@CR16],[@CR19],[@CR21]--[@CR23]^, the same treatment regimen was used for all study participants. Six studies partitioned the study participants into subgroups and followed a different treatment strategy for each subgroup^[@CR14],[@CR17],[@CR18],[@CR20],[@CR24],[@CR25]^. Each treatment strategy was considered as a separate observation in our analysis and was included separately in its respective subgroup.

The efficacy from the studies that reported extractable data on the treatment regimen used varied from 50 to 100% (Fig. [3](#Fig3){ref-type="fig"}). Studies were sub-grouped based on the SOF-dose administered. The pooled efficacy of the sofosbuvir regimen was 92% (95% CI 80--99%) in patients administered a 400 mg alternate day dose, 98% (95% CI 96--100%) in those administered a 400 mg daily dose, and 100% (95% CI 95--100%) in patients administered a 200 mg daily dose (Fig. [3](#Fig3){ref-type="fig"}). A sub-group analysis was not performed for the various other DAA used in the treatment regimens, due to the large variability of DAA used. Ribavirin was used in 6 studies^[@CR10],[@CR13],[@CR14],[@CR16],[@CR18],[@CR28]^, simeprevir in 3^[@CR15],[@CR17],[@CR21]^, ledipasvir in 8^[@CR17],[@CR20]--[@CR22],[@CR25]--[@CR27],[@CR29]^, daclatasvir in 9^[@CR10],[@CR11],[@CR14],[@CR16]--[@CR20],[@CR24]--[@CR29]^ and velpatasvir in 2 studies^[@CR12],[@CR23]^ (Table [1](#Tab1){ref-type="table"}).Figure 3Forest plot of included studies sub-grouped by sofosbuvir dose. Individual and combined estimates of the efficacy of SOF-based therapy for each sub-group with 95% confidence intervals. *ES* effect size (efficacy).

Six studies included extractable data on the efficacy of SOF-based therapy in patients with cirrhosis^[@CR11],[@CR12],[@CR17]--[@CR19],[@CR24]^. The pooled estimate of the efficacy of SOF-based therapy among HCV positive patients on maintenance hemodialysis with cirrhosis was 97% (95% CI 84--100%), ranging from 67 to 100% (Supplementary Fig. [1](#MOESM1){ref-type="media"}).

A total of 16 studies reported extractable data on adverse events^[@CR10]--[@CR14],[@CR16]--[@CR19],[@CR21]--[@CR23],[@CR25],[@CR27]--[@CR29]^ (Table [2](#Tab2){ref-type="table"}). The most commonly reported adverse events were anemia (10 studies)^[@CR10],[@CR12]--[@CR14],[@CR16]--[@CR18],[@CR21],[@CR23],[@CR28]^, headache (8 studies)^[@CR12],[@CR17],[@CR21]--[@CR23],[@CR25],[@CR27],[@CR29]^, fatigue (6 studies)^[@CR13],[@CR16],[@CR17],[@CR19],[@CR23],[@CR25]^, nausea or vomiting (5 studies)^[@CR19],[@CR21],[@CR23],[@CR25],[@CR29]^, insomnia (5 studies)^[@CR13],[@CR19],[@CR21],[@CR23],[@CR29]^ and rash or itching (4 studies)^[@CR13],[@CR17],[@CR21],[@CR29]^. The most frequent adverse event was fatigue with an overall pooled prevalence of 16% (95% CI 5--29%) (Fig. [4](#Fig4){ref-type="fig"}). Anemia ranged from 0 to 56%, with an overall pooled prevalence of 15% (95% CI 3--31%) (Fig. [5](#Fig5){ref-type="fig"}). Anemia was more prevalent in treatment regimens containing ribavirin (46%, 95% CI 33--59%) compared to regimens that did not contain ribavirin (3%, 95% CI 0--9%). The overall pooled prevalence of headache was 7% (95% CI 3--13%), nausea or vomiting 14% (95% CI 4--27%), insomnia 3% (95% CI 0--8%), rash or itching 7% (95% CI 0--18%). Two studies reported drug discontinuation due to adverse events^[@CR18],[@CR24]^. Cheema et al. reported a treatment related serious adverse event (drug induced rash) in 1 patient^[@CR24]^, and Gupta et al. reported that 1 patient developed recurrent hypoglycemia which improved after stopping therapy^[@CR18]^.Table 2Adverse events reported for sofosbuvir-based regimens.StudyNumber of patientsAnemia (%)Fatigue (%)Rash or itching (%)Headache (%)Nausea/vomiting (%)Insomnia (%)Agarwal et al.^[@CR14]^6223 (37%)NRNRNRNRNRAkhil et al.^[@CR10]^229 (41%)NRNRNRNRNRChoudhary et al.^[@CR16]^73 (43%)2NRNRNRNRDesnoyer et al.^[@CR17]^123 (25%)2 (17%)1 (8%)2 (17%)NRNRGupta et al.^[@CR18]^71 (14%)NRNRNRNRNRHe et al.^[@CR19]^33NR13 (39%)NRNR131Sperl et al.^[@CR11]^60NRNRNRNRNRSurendra et al.^[@CR22]^21NR0NR1 (5%)00Singh T. et al.^[@CR21]^81 (13%)NR1 (13%)1 (13%)11Borgia et al.^[@CR23]^594 (7%)8NR1081Seo et al.^[@CR13]^95 (56%)22NRNR1Lin et al.^[@CR27]^7NRNRNR1NRNRDebnath et al.^[@CR25]^180 (0%)2NR14NRSingh A. et al.^[@CR29]^390 (0%)NR1144Mandhwani et al.^[@CR28]^7328 (%)NRNRNRNRNRGaur et al.^[@CR12]^312 (38%)NRNR1NRNR*NR* Not reported.Figure 4Forest plot of included studies that reported adverse events. Individual and combined estimates of prevalence of each adverse event with 95% confidence intervals. *ES* effect size (prevalence).Figure 5Forest plot of included studies that reported anemia as an adverse event. Individual and combined estimates of prevalence of each adverse event with 95% confidence intervals. *ES* effect size (prevalence).

Discussion {#Sec3}
==========

A systematic review and meta-analysis was conducted to determine the safety and efficacy of SOF-based regimens in the treatment of HCV infection among patients requiring maintenance hemodialysis. Among the 934 studies that were identified in our database search, 20 studies met our inclusion criteria. Overall, the pooled estimate of efficacy, based on SVR12, was 95%, ranging from 73 to 100%. Using meta-regression analyses, no statistically significant differences were identified for patient demographics, use of different types of DAA in addition to SOF, or HCV genotypes. Among the studies that reported the dose of SOF, no statistically significant differences in SVR12 were noted with pooled estimates of 92%, 98%, and 100% for SOF doses of 400 mg on alternate days, 400 mg daily and 200 mg daily, respectively.

Among the studies that reported adverse events, anemia was the most common with a pooled prevalence of 15%. A total of 10 (50%) studies reported anemia as an adverse event. Among these, 6 (60%) included ribavirin in the SOF-based regimens. Since ribavirin frequently causes anemia, a subset analysis was performed to compare rates of anemia among ribavirin and ribavirin-free regimens^[@CR30]^. The prevalence of anemia was significantly higher in regimens containing ribavirin (46%) compared to ribavirin-free regimens (3%). Other adverse events identified in this meta-analysis, included fatigue, rash or itching, headaches, insomnia and nausea or vomiting with pooled estimates of 16%, 7%, 7%,3% and 14%, respectively.

Several large-scale studies evaluated the efficacy and safety among patients with HCV infection and severe renal impairment, treated with SOF-based regimens^[@CR8],[@CR9]^. A longitudinal prospective study by Saxena et al. compared outcomes of HCV infection between 1716 pts with estimated glomerular filtration rate (eGFR) \> 45 ml/min/1.73 m^2^ to 73 patients with an eGFR ≤ 45, of which five were on hemodialysis. Patients were treated with SOF 400 mg daily and 60% also received ribavirin. Among patients with eGFR ≤ 45, SVR12 was achieved among 83% of patients. Reported rates of adverse events, in this subset of patients, were similar to our study, with anemia, fatigue and headaches occurring in 30%, 30% and 14% of patients, respectively. Rash or itching was not reported^[@CR9]^. A meta-analysis by Li et al. evaluated studies of SOF-based regimens among HCV positive patients with stage 4 or 5 chronic kidney disease (GFR \< 30 mL/min/1.73 m^2^). Their outcome of efficacy combined SVR at 12 and 24 weeks. Twenty-one studies were included, with a total of 717 HCV infected patients, of whom 306 (58.4%) were on either hemodialysis or peritoneal dialysis. Doses of SOF varied and a subset also received ribavirin. Among patients requiring dialysis, the pooled SVR12/24 was 95%. Rates of anemia, fatigue, headache, rash or itching were not reported^[@CR8]^. Lastly, in November 2019, the U.S. Food and Drug Administration (FDA) updated the prescribing of several SOF-based regimens, which now states that no dosage adjustment is required for patients with any degree of renal impairment. In the updated labeling report for sofosbuvir/velpatasvir, for example, the FDA reported an overall SVR of 95% among 59 patients requiring hemodialysis and peritoneal dialysis. Adverse events were not provided^[@CR31]^. Our findings support the notion that the use of Sofosbuvir based regimens in patients receiving hemodialysis is both safe and effective. In our analysis, hemodialysis did not seem to be an unfavorable factor, in terms of safety and efficacy, when compared to other meta-analyses which included Hepatitis C patients without renal disease^[@CR32],[@CR33]^.

There are several limitations that warrant discussion. First, substantial heterogeneity was found among studies, which we addressed by using a random effects model instead of a fixed effects model. Furthermore, meta-regression analysis of specific variables, including patient demographics, HCV genotype and SOF dose did not identify any statistically significant differences. Second, although some publications reported lower SVR rates based on different SOF-based regimens, a subset analyses of types of SOF-based regimens and a comparison of NS5A and NS3 protease inhibitor regimens could not be performed due to the small number of studies in each group. Future studies will need to compare differences in efficacy and safety among SOF-based regimens using different DAA. Third, efficacy by specific HCV genotype could not be determined, again due to the small number of patients and that data pertaining to specific genotypes and outcomes were not extractable.

In conclusion, our findings support that the use of SOF-based regimens in the treatment of HCV infection among patients requiring hemodialysis is both safe and effective. Future randomized controlled studies are needed to confirm these results and to evaluate the optimal SOF-based treatment regimen.

Methods {#Sec4}
=======

This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA)^[@CR34]^ and has been registered in PROSPERO (CRD42018116632, <https://www.crd.york.ac.uk/PROSPERO>).

Search strategy {#Sec5}
---------------

A systematic search of Pubmed and Embase databases was performed to identify studies reporting the efficacy and safety of SOF-based regimens for the treatment of HCV positive patients on maintenance hemodialysis. The following search term was used: (end stage renal disease OR renal replacement therapy OR chronic kidney failure OR severe renal impairment OR chronic kidney disease OR hemodialysis) AND (sofosbuvir). Results were limited to the English language and publication dates until May 22, 2020. Additionally, references of systematic reviews focusing on HCV treatment were reviewed manually.

Eligibility criteria and study selection {#Sec6}
----------------------------------------

Two reviewers (KB and EMCD) independently screened and evaluated the studies that were potentially eligible for inclusion with discrepancies were resolved either between the two reviewers or a third party (FS), if consensus could not be reached. Studies were included if they reported extractable data on the number of maintenance hemodialysis patients that completed a SOF-based regimen and had values for a sustained virologic response 12 weeks after the completion of treatment (SVR12). Our primary outcome of interest was the efficacy of SOF-based therapy in HCV positive patients on maintenance hemodialysis. Regimen efficacy was defined as the proportion of patients that had SVR12. As a secondary outcome of interest, we evaluated the safety of SOF-based regimens, by quantifying the proportion of patients with reported adverse events.

Studies that reported only aggregate data on patients, regardless of their dependency on hemodialysis, were excluded as were opinion pieces and conference abstracts. Studies that focused on patients \< 18 years old, HIV positive patients or transplant recipients were also excluded. SOF-based regimens that included pegylated interferon were also excluded.

Data extraction and quality assessment {#Sec7}
--------------------------------------

For each included study, we extracted the following information: study period, country, type of study, age, gender, HCV genotype, number of patients on a SOF-based therapy, other DAA used in treatment regimen, SOF dose, number of patients who had SVR12, and adverse events. Data extraction was performed by FS and checked for accuracy by EMCD.

We assessed the quality of the eligible studies using the Newcastle--Ottawa Scale^[@CR35]^. A maximum of six stars could be assigned to each study, as the parameters "selection of the non-exposed cohort" and "comparability between cohorts" were not applicable to our analysis. High quality studies were defined as studies that received ≥ 5 stars (Supplementary Table [1](#MOESM1){ref-type="media"}).

Data synthesis and analysis {#Sec8}
---------------------------

We performed a random effects meta-analysis to estimate the pooled efficacy of SOF-based therapy in HCV positive patients on dialysis, using the DerSimonian and Laird approach^[@CR36]^. The Freeman Tukey double arcsine transformation was used to stabilize the variances^[@CR37]^. We selected a random effects model, because we assumed that the effects are heterogeneous due to differences in the study design, SOF dosage and combination drugs of each study. Studies were grouped by regimen dosage where possible, and a random effects meta-analysis was carried out in these sub-groups. We assessed the heterogeneity among studies and subgroups using the I^2^ statistic^[@CR38]^. The Egger's test was used to explore publication bias and small study effects^[@CR39]^.

To evaluate the safety of the SOF-based regimens, we performed a random-effects meta-analysis for each adverse event reported in 3 or more studies, and estimated the pooled proportion of patients that reported each adverse event. A meta-regression analysis was also conducted to investigate the extent to which the differences in study characteristics were correlated with the between study heterogeneity^[@CR40]^. For our review, we used an intention to treat analysis. Patients lost to follow-up were considered as treatment failures.

Stata v15 (Stata Corporation, College Station, TX, USA) was used to perform the statistical analysis. The statistical significance threshold was set at 0.05.
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